Eisai is eliminating 121 jobs across its US operations, representing a 6.83% reduction in its US workforce13.
The layoffs will primarily affect commercial, medical and corporate service functions13.
57 employees at Eisai's US headquarters in Nutley, New Jersey will be impacted, with layoffs effective between March 31 and May 30, 202536.
The restructuring aims to streamline operations, improve efficiency, and ensure long-term sustainability39.
Eisai remains committed to the US market, particularly in addressing unmet medical needs in cancer, Alzheimer's disease, and other neurological conditions39.
The layoffs come as Eisai anticipates potential growth for its Alzheimer's drug Leqembi, which has shown steady but slow sales growth since its 2023 FDA approval67.
This restructuring follows previous layoffs in early 2023 when Eisai cut 91 US jobs after selling its epilepsy medication Fycompa9.
The pharmaceutical industry in New Jersey has seen several recent layoffs, including cuts at Bristol Myers Squibb, Bayer, and Johnson & Johnson6.
Sources:
1. https://www.bmpharmaceuticals.com/eisai-to-part-ways-with-121-employees-amid-new-us-restructuring-effort/
3. https://www.biospace.com/job-trends/eisai-will-trim-about-7-of-us-workforce-including-new-jersey-employees
6. https://njbiz.com/more-layoffs-coming-to-njs-pharma-sector/
7. https://www.fiercepharma.com/pharma/eisai-execs-flag-leqembi-expansion-phase-horizon-alzheimers-med-continues-grow-steadily
9. https://www.fiercepharma.com/pharma/eisai-part-ways-121-employees-amid-new-us-restructuring-effort